Sofamor Danek paying up to $50 mil. for Genetics Institute's rhBMP-2 for spinal fusion.
This article was originally published in The Gray Sheet
Executive Summary
SOFAMOR DANEK TO DEVELOP GENETICS INSTITUTE'S rhBMP-2 FOR SPINAL FUSION under a collaborative alliance announced Feb. 16. With the deal, Sofamor Danek is gaining exclusive North American rights to develop and commercialize products based on Genetics Institute's recombinant human bone morphogenetic protein to induce bone growth in spinal reconstruction procedures.